Self-medication with antimycotic nail polishes plays an important role in Germany due to the numerous OTC drugs available and an increasing number of onychomycosis cases. Older patients in particular are more frequently affected due to slower nail growth and the possible existence of predisposing diseases [1]. But the prevalence is also increasing in children [2]. This makes guideline-based recommendations regarding diagnosis, therapy and prophylaxis of onychomycosis all the more important.

The recently published guideline „Onychomycosis“ (AWMF register no.: 013-003, 2022) under the direction of Professor Pietro Nenoff, MD, represents the first update of the diagnosis, therapy and prophylaxis of onychomycosis since 2006 [3]. In addition, current treatment approaches such as laser therapy have been evaluated. Also important are the recommendations included on onychomycosis in children, the treatment of which, in Germany, falls predominantly in the area of off-label use due to the lack of clinical studies involving children. Furthermore, the treatment of athlete’s foot (tinea pedis, pedum) receives a particular mention, since onychomycosis often develops from an existing case of athlete’s foot and the risk of recurrence after successful therapy increases if it is not treated simultaneously. For prophylaxis, the long-term use of antimycotic nail polish preparations in reduced application frequency is considered, as well as the use of disinfectant shoe sprays with quaternary ammonium compounds (didecyl dimethyl ammonium chloride and polyhexamethylenebiguanide HCl) and washing of contaminated laundry at 60 °C.

Nail fungus (onychomycosis) is a chronic fungal infection of the fingernails and/or toenails and leads to slow destruction of the nail plate, as the fungus feeds on the keratin of the nail. The infection is progressive if left untreated and has no self-healing tendency (Tab. 1). The pathogens can vary depending on the climatic zones. In temperate climate zones – alongside Germany, other European countries and North America – the pathogens are predominantly dermatophytes. A nail fungus infection that is exclusively caused by dermatophytes is also called tinea unguium. In Germany, the most common dermatophyte causing nail fungus is Trichophyton rubrum. Candida onychomycosis is less common and onychomycosis caused by moulds is very rare. If yeast fungi (Candida spp.) are positively detected, secondary colonisation without significance as illness should always be considered. When yeasts are detected from fingernails, onychomycosis is more likely than when Candida species are cultured from toenail material. Moulds – also called „nondermatophyte moulds“ (NDM) – occur more frequently in subtropical and tropical regions. Therefore, the pathogens will not be discussed further here.

Diagnosis – treatment of onychomycosis based on clinical picture and pathogen detection

The therapy is based on the clinical picture of the infection and the detection of the pathogen, usually by direct microscopy using a native preparation and cultural detection. Molecular detection, for example by means of polymerase chain reaction (PCR), is not the rule, but is recommended due to its high sensitivity and specificity. The correct collection of material is particularly important for successful diagnosis. Nail chips should, as far as possible, be obtained from the proximal border of the visible nail change (ideally by milling). With regard to the clinical picture of onychomycosis, the guideline distinguishes five forms: distolateral subungual onychomycosis (DSO), proximal subungual onychomycosis (PSO), proximal white subungual onychomycosis (PWO), white superficial onychomycosis (WSO) and total dystrophic onychomycosis (TDO). DSO is the most common form and can be treated locally if the nail matrix is not affected. Further criteria for self-medication are a maximum of 40% of the...
Evidence for Self-Medication

2023 Wissenschaftliche Verlagsgesellschaft Stuttgart

and surgical extraction of fungus-infected nails, which was mycological cure cannot be achieved with atraumatic nail treatment of onychomycosis to reduce the fungus-infected bed, especially after atraumatic nail removal using urea milling machine. Acrylic-containing polish formulations acrylic nail polish. Studies on acrylic amorolfine polishes are not mentioned in the meta-analysis.

As soon as the nail matrix is infected or a moderate to severe infection is present, oral (systemic) therapy is always recommended, provided there are no contraindications. Antifungal combination therapy with a local antifungal polish is recommended due to synergistic effects. Systemic therapy with terbinafine for infections caused by dermatophytes is the drug of choice because of its good fungicidal rather than only fungistatic efficacy. Neither the risk of side effects nor the number of relapses differed between terbinafine and azole antifungals. Other ergosterol inhibitors for systemic therapy are the predominantly fungistatic azoles such as itraconazole and fluconazole. According to the guideline commission, the extent to which itraconazole embedded in SUBA (super bioavailability) polymer represents an alternative to conventional itraconazole still needs to be investigated.

The most important therapeutic recommendations are listed in Table 2.

Onychomycosis in children

Although fungal nail infections in children are atypical, increasing prevalence figures give reason for concern and education about appropriate treatment options. In their systematic review, Vestergaard-Jensen et al. [7] examined the changes in prevalence of onychomycosis in children. Population studies from 1972 to 2014 were evaluated and prevalences ranging from 0% to 7.66% with an overall discrete increase of 0.66% were noted (not statistically significant). The guideline authors also addressed the topic for the first time and included the section „Onychomycosis in children“ in the guideline update [3].
Because of the faster nail growth in children, local antifungal therapy can always be considered as a first step. Systemic therapy is recommended in the advanced stage, but is often rejected by the parents or guardians. Adequate education plays an important role here. Modern systemic antimycotics such as terbinafine, fluconazole or itraconazole are not approved for use in children in Germany due to a lack of clinical data (unlike, for example, terbinafine in Austria).

Tab. 2. Overview of guideline-based treatment (according to Nenoff P et al. S1 guideline on onychomycosis [3])

### Local treatment

<table>
<thead>
<tr>
<th>Nail polish preparation</th>
<th>Application frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amorolfine HCl 5% Acrylic nail polish (up to 80% nail surface)</td>
<td>1 x per week</td>
</tr>
<tr>
<td>Ciclopirox 8% acrylic nail polish</td>
<td>Every 2 days, from 2nd month 2 x per week</td>
</tr>
<tr>
<td>Ciclopirox 8% nail polish water-soluble + HP chitosan</td>
<td>1 x daily</td>
</tr>
<tr>
<td>Terbinafine (78.22 mg terbinafine/ml nail polish) water-soluble nail polish + HP chitosan</td>
<td>1 x daily for 4 weeks, then 1 x per week</td>
</tr>
</tbody>
</table>

### Systemic treatment

For moderate and severe onychomycosis, it is recommended, provided there are no contraindications, to always treat orally (systemically). A combination antifungal therapy (oral and topical) should be aspired to.

<table>
<thead>
<tr>
<th>Terbinafine</th>
<th>Fluconazole</th>
<th>Itraconazole</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 mg 1 x daily</td>
<td>150 mg 1 x per week</td>
<td>Interval treatment: 400 mg daily (2 x 2 capsules à 100 mg per day [400 mg]) for 1 week, then three weeks’ break = 1 pulse. Three pulses (1 week itraconazole + 3 weeks’ break) or 3 months for toenail infection. For fingernail onychomycosis a shorter time, possibly only 2 pulses.</td>
</tr>
</tbody>
</table>

- Toenails affected: 12 weeks
- Only fingernails affected: 6 weeks

- Intermittent low-dose terbinafine therapy (off-label use, not supported by studies, „expert opinion“)
  - 250 mg terbinafine daily for 3 days, then 250 mg once per week until clinical cure (up to 1 year)

- Intermittent low-dose itraconazole therapy (off-label use, not supported by studies, „expert opinion“)
  - Loading phase: 2 x 100 mg SUBA-itraconazole (2 x 2 capsules à 50 mg) for 3 days, then maintenance therapy once a week 2 x 100 mg SUBA-itraconazole (= 2 x 2 capsules à 50 mg) until clinical cure (up to 1 year)

### Selection of the antifungal

- **Dermatophytes:**
  - Trichophyton rubrum (most frequent causative agent)
  - Trichophyton interdigitale (second most frequent causative agent)
- **Yeasts:**
  - Candida albicans and Candida parapsilosis (often on fingernails)
- **Moulds:**
  - Scopulariopsis brevicaulis (common)

- **Topical:** Amorolfine or ciclopirox nail polishes
- **Systemic:** Terbinafine (T. rubrum + T. interdigitale), fluconazole (T. rubrum), itraconazole (T. rubrum + T. interdigitale)

- **Yeasts:**
  - If necessary, additionally systemic: Fluconazole p.o. (continuous or interval therapy) or itraconazole, in the case of Candida parapsilosis terbinafine is also possible

- **Moulds:**
  - Terbinafine p.o. works in individual cases

HP-Chitosan: Biopolymer Hydroxypropyl chitosan (HPCH); SUBA: Super-bioavailability-Polymer
and Switzerland, where it is approved for use in children). Especially for terbinafine, there has been good experience regarding the weight-adapted therapy of onychomycosis in children. Griseofulvin was approved for treating children, but since 2018 has no longer been on the market in Germany and could only be ordered via the international pharmacy. However, this antifungal is not recommended for treating onychomycosis in children due to lower efficacy, high relapse rate, and frequent side effects.

The most important therapeutic recommendations of the guideline on onychomycosis in children are summarised in Table 3.

### Prophylaxis after treatment of onychomycosis

According to the guidelines, a prophylactic further treatment of the nail with antifungal nail polishes in reduced application frequency after successful onychomycosis therapy can be considered in individual cases. This recommendation is not evidence-based due to lack of clinical studies. The treatment of existing athlete’s foot with antifungal sprays, solutions or creams is recommended and presumably also has a prophylactic effect to reduce the recurrence risk of onychomycosis.

Another prophylactic measure is shoe disinfection. Fungal elements can survive in shoes for up to six months or longer [9]. According to the guideline, a dosage spray with an aqueous solution that does not contain propellant gas or alcohol, does not attack the colour of the shoes and is highly effective due to two quaternary ammonium compounds (didecyldimethylammonium chloride and polyhexamethylene biguanide HCl) is particularly suitable. Laundry that has direct contact with the mycosis, for example socks and towels, should be washed at 60 °C [9].

### All information is given to the best of our knowledge and belief, but no liability is accepted in individual cases, especially for dosage recommendations, which must be checked individually and updated.

#### Literature


---

### Table 3. Guideline recommendation for local and systemic therapy in childhood (according to Nenoff P et al. S1 guideline onychomycosis)

<table>
<thead>
<tr>
<th>Local and systemic therapy in childhood</th>
<th>Topical therapy is recommended for initial onychomycosis in childhood. For advanced onychomycosis in childhood, systemic therapy is recommended.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Terbinafine (off-label use)</strong></td>
<td><strong>Fluconazole (off-label use)</strong></td>
</tr>
<tr>
<td>62.5 mg/day for a bw of &lt;20 kg or 125 mg/day for &gt;20–40 kg bw or 250 mg/day for &gt;40 kg bw. Continuous administration for 12 weeks.</td>
<td>3–5 mg/kg bw (up to max. 50 mg/d) until healthy nail outgrowth. 5 mg/kg bw once daily. Capsules with the main meal, the solution one hour after the meal at the earliest on an empty stomach. (Practical procedure: 50 mg daily for bw &lt;20 kg or 100 mg daily for &gt;20 kg bw. Under 10 kg bw strictly body weight-adapted.</td>
</tr>
<tr>
<td>Loading phase: Terbinafine dosed according to body weight (see above) daily for 3 days, then one dose per week until clinical cure (up to 1 year).</td>
<td>Intermittent therapy 6 mg/kg bw once a week for 3–6 months for onychomycosis of the fingernails and 6–12 months for toenail infection. Until clinical cure (up to 1 year). Intermittent low-dose therapy (not supported by studies; „Expert opinion“)</td>
</tr>
<tr>
<td>Intermittent low-dose therapy (not supported by studies; „Expert opinion“)</td>
<td><strong>Itraconazole (off-label use)</strong></td>
</tr>
</tbody>
</table>

---

**The complete guideline contents (register number 013 - 003) are available on the AWMF portal** (https://www.awmf.org/leitlinien/detail/I/013-003.html)
Conflicts of interest: M. Niehaus is an employee of Almirall Hermal GmbH.

Disclosure: Publication funded by Almirall Hermal GmbH; P. Mayser receives a fee from Almirall Hermal for reviewing the contents.